Form 4 for STOK Stoke Therapeutics, Inc.
Accepted 2026-03-17 00:00:00 ET · period of report 2026-03-15 · accession 0001774690-26-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-17 | 2026-03-15 | STOK | Leggett Thomas | CFO | M - OptEx | $0.00 | +14.8K | 14.8K | New | $0 |
| D | 2026-03-17 | 2026-03-15 | STOK | Leggett Thomas | CFO | M - OptEx | $0.00 | -14.8K | 44.2K | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-15 | M | A | 14,750 | $0.00 | 14,750 | D | — | — | |
| 2 | Derivative | Restricted Stock Units | 2026-03-15 | M | D | 14,750 | $0.00 | 44,250 | D | — · — to 2029-03-15 | 14,750 Common Stock | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. (F2) The award vested or vests as to 1/4 of the total award annually beginning on March 15, 2026, subject to the reporting person's continued service to the Issuer through each vesting date. |